Shafiee Gita, Heshmat Ramin, Ostovar Afshin, Khatami Fatemeh, Fahimfar Noushin, Arzaghi Seyed Masoud, Gharibzadeh Safoora, Hanaei Sara, Nabipour Iraj, Larijani Bagher
Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Osteoporosis Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
J Diabetes Metab Disord. 2020 May 29;19(2):727-734. doi: 10.1007/s40200-020-00553-w. eCollection 2020 Dec.
This study proposed to compare the prevalence and risk factors for sarcopenia by EGWSOP-1 and EWGSOP-2 diagnostic criteria in Iran.
This cross-sectional study was conducted based on the data collected during the Bushehr Elderly Health (BEH) Program, stage II. Sarcopenia was defined as 3 definitions: EWGSOP-1(with Iranian cut off), EWGSOP-2(with Iranian cut off), EWGSOP-2(with European cut off) definition. We evaluated the age-standardized prevalence of sarcopenia in both genders. Regression analysis was used to show the associations in the adjusted models.
Among 2426 participants, age-standardized prevalence of sarcopenia, and severe sarcopenia by EWGSOP-1 were 19.7%, and 12.9%, in men and 13.6%, and 16.7% in women, respectively. When we used EWGSOP-2 (with Iranian cut-off) criteria, these values were 10.5%, and 12.7% among men and 7.13% and 16.5% in women, respectively. The prevalence sarcopenia and severe sarcopenia by EWGSOP-2 (with European cut-off) were 12.7%, and 13.4% in men and 5.42%, and 13.7% in women, respectively. In both genders, getting older and high-fat mass were positively associated with sarcopenia, and BMI had a significant inverse association in both genders and all defintions.
Results showed that a prevalence of sarcopenia varied largely by using different criteria, in both sexes. EWGSOP2- defined sarcopenia prevalence was lower than that defined using EWGSOP-1 criteria due to different diagnostic factors to detect sarcopenia. Some adverse outcomes should be considered for evaluating sarcopenia to compare the accuracy of EWGSOP-1 and EWGSOP-2.
本研究旨在比较伊朗采用欧洲老年人肌肉减少症工作组(EWGSOP)-1和EWGSOP-2诊断标准时肌肉减少症的患病率及危险因素。
本横断面研究基于布什尔老年人健康(BEH)项目第二阶段收集的数据开展。肌肉减少症有3种定义:EWGSOP-1(采用伊朗截断值)、EWGSOP-2(采用伊朗截断值)、EWGSOP-2(采用欧洲截断值)。我们评估了两性中年龄标准化的肌肉减少症患病率。采用回归分析来显示校正模型中的关联。
在2426名参与者中,根据EWGSOP-1标准,男性肌肉减少症和严重肌肉减少症的年龄标准化患病率分别为19.7%和12.9%,女性分别为13.6%和16.7%。当采用EWGSOP-2(采用伊朗截断值)标准时,男性中的这些值分别为10.5%和12.7%,女性分别为7.13%和16.5%。根据EWGSOP-2(采用欧洲截断值)标准,男性肌肉减少症和严重肌肉减少症的患病率分别为12.7%和13.4%,女性分别为5.42%和13.7%。在两性中,年龄增长和高脂肪量与肌肉减少症呈正相关,而体重指数(BMI)在两性及所有定义中均与肌肉减少症呈显著负相关。
结果表明,使用不同标准时,两性中肌肉减少症的患病率差异很大。由于检测肌肉减少症的诊断因素不同,EWGSOP-2定义的肌肉减少症患病率低于使用EWGSOP-1标准定义的患病率。在评估肌肉减少症以比较EWGSOP-1和EWGSOP-2的准确性时,应考虑一些不良后果。